Online inquiry

IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5395MR)

This product GTTS-WQ5395MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD2 gene. The antibody can be applied in Psoriasis, severe chronic plaque research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001328609.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 914
UniProt ID P06729
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5395MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ667MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ15746MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ13241MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ8109MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ6574MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ6253MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CR-6261
GTTS-WQ13882MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ12819MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMS721
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW